Do Urate Targets Influence CV Risk?
Researchers examine whether achieving treat-to-target serum urate levels with urate-lowering treatment affects long-term cardiovascular outcomes in patients with gout.
-
By
-
Kathryn Wighton
-
January 30, 2026
-
Clinical Scorecard: Do Urate Targets Influence CV Risk?
At a Glance
| Category | Detail |
|---|
| Condition | Gout |
| Key Mechanisms | Achievement of serum urate targets is associated with reduced cardiovascular risk. |
| Target Population | Adults with newly diagnosed gout, particularly those with high cardiovascular risk. |
| Care Setting | Primary care and outpatient settings. |
Key Highlights
- Only 27% of patients achieved serum urate targets within 12 months.
- Achieving urate levels <6 mg/dL linked to 9% relative risk reduction for major adverse cardiovascular events (MACE).
- Stricter target of <5 mg/dL associated with 23% relative risk reduction.
- 99% of patients were prescribed allopurinol.
- 5-year cardiovascular event-free survival was 89% in the treat-to-target group.
Guideline-Based Recommendations
Diagnosis
- Monitor serum urate levels in patients with gout.
Management
- Implement urate-lowering treatment (ULT) using a treat-to-target approach.
Monitoring & Follow-up
- Regularly assess serum urate levels to ensure targets are met.
Risks
- Consider cardiovascular risk factors when managing gout.
Patient & Prescribing Data
109,504 adults with newly diagnosed gout.
Allopurinol is the primary medication prescribed for urate-lowering.
Clinical Best Practices
- Aim for serum urate levels <6 mg/dL in gout management.
- Follow a treat-to-target strategy to improve cardiovascular outcomes.
- Monitor for gout flares and adjust treatment as necessary.
References
